A break-through technology for high-throughput analyses
BioCopy provides high-throughput analyses for the development of immunotherapeutics and novel vaccines in the field of oncology and infectious diseases. At BioCopy, we are convinced that this holds the key to the medicine of the future.
We combine next generation microarrays with our highSCORE system and measure the binding kinetic of thousands of molecules fast and label-free – on one single chip in one measurement.
If you need to find out “which molecule binds best”, BioCopy is your perfect match! Our unique technology is based on the team’s wide- ranging expertise in biochemistry and microsystems engineering.
Founded as a university spin-off in 2016, BioCopy is a multinational company headquartered in Switzerland with a large and modern R&D facility in Germany.
At BioCopy, we are defining new standards in our research and development. Work with us! Together, we can combine our technologies and expertise to develop the therapeutics of tomorrow.
Multi-award winning start-up
Forbes Magazine listed BioCopy in 2021 as one of the 30 Spin-offs to watch.
| |
The Royal Society of Chemistry (RSC) Emerging Technologies of London
Lists the BioCopy concepts “AptaSWIFT” and “immune2day” in the TOP 10 of Health technologies in 2015 |
Collaborations
| In July 2021, BioCopy and Immatics announced a collaboration to accelerate T cell receptor (TCR) characterization. This includes the analysis of TCR interaction with hundreds of peptide-HLA complexes in a single measurement. | |
| As industry partner in the publicly funded project BISKUIT, Biocopy focused on the development of an automated platform for point-of-care diagnostics and the production of antigen microarrays for serological diagnostics. Together with the University of Freiburg, BioCopy developed a new method for the label-free detection and characterization of SARS-CoV-2 specific antibodies. | |
| Together with the Swiss Federal Institute of Virology and Immunology (IVI), BioCopy has been working on research into a vaccine and the development of new diagnostic methods against African swine fever (ASF) since the beginning of 2021. | |
| An early collaboration of BioCopy with CORAT Therapeutics has helped to identify an antibody which is now being tested in a Phase II clinical trial for the treatment of COVID-19 patients with moderate to severe symptoms. |
Facts and Figures
29 team members
| |
Advisory board with professional background in the pharmaceutical industry
| |
State-of-the-art lab and office space
| |
Broad patent portfolio of currently 16 patent families
| |
2.5 million binding kinetic analyses since 10/2019… and counting
|